mBio · 2019 · 56 citations · 25 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationInnate ImmunityVaccinologyAntiviral ImmunityInnate Immune ResponseVaccinationVaccine PlatformsVaccine-preventable DiseasesViral VaccinesAntiviral Innate SignalingBiomarkersEarly Detection BiomarkersEbola VaccinesGene Expression SignaturesHost Gene ExpressionPhase Iii Clinical TrialsPhase Iii Vaccine Trials
Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), a deadly disease and major public health threat worldwide. A safe and highly efficacious vesicular stomatitis virus-based vaccine against EBOV is the only platform that has successfully completed phase III clinical trials and has been used in recent and ongoing outbreaks. Earlier studies showed that antibodies are the main mode of protection when this vaccine is administered 28 days before EBOV challenge. Recently, we showed this vaccine can provide protection when administered as early as 3 days before challenge and before antibodies are detected. This study seeks to identify the mechanisms of rapid protection, which in turn will pave the way for improved vaccines and therapeutics. Additionally, this study provides insight into host gene expression signatures that could provide early biomarkers to identify infected individuals who are at highest risk of poor outcomes.
25
The Immunological Genome Project: networks of gene expression in immune cells
Tracy Heng, Michio W. Painter, Kutlu G. Elpek et al. · Nature Immunology · 2008 · 1.9K citations
Life Sciences, Genetics, Immunology +16
Guide for the Care and Use of Laboratory Animals (8th edn)
Udo Albus · Laboratory Animals · 2012 · 1.7K citations · Full text
Ana María Henao-Restrepo, Ira M. Longini, Matthias Egger et al. · The Lancet · 2015 · 796 citations · Full text